Health mission Health mission
In August 2019, Pretomanid, drug developed by the non-profit organization, TB Alliance, has received U.S. Federal Drug Administration (FDA) approval for treatment of extensively drug-resistant tuberculosis or treatment-intolerant/non-responsive multidrug-resistant tuberculosis in combination regimen with bedaquiline and linezolid. Multidrug-resistant tuberculosis (MDR-TB) is caused by an organism that is resistant to at ...
Read More »New Treatment for Highly Drug-Resistant Tuberculosis (TB) was Approved
